Results 41 to 50 of about 328,808 (245)

A dual readout embryonic zebrafish xenograft model of rhabdomyosarcoma to assess clinically relevant multi-receptor tyrosine kinase inhibitors

Frontiers in Oncology
BackgroundRhabdomyosarcoma (RMS) is a highly aggressive soft tissue sarcoma, affecting children and adolescents, with poor prognosis in some patient groups. Better therapeutic regimens and preclinical models to test them in are needed.
Joseph W. Wragg, Emma L. Gray, Rui Monteiro, Jo R. Morris, Andrew D. Beggs, Ferenc Müller, Susanne A. Gatz, Susanne A. Gatz   +7 more
doaj   +1 more source

Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

Frontiers in Pharmacology, 2022
Antibody-drug conjugates (ADCs) have begun to fulfil their promise as targeted cancer therapeutics with ten clinical approvals to date. As the field matures, much attention has focused upon the key factors required to produce safe and efficacious ADCs ...
Nick Evans, Ruslan Grygorash, Paul Williams, Andrew Kyle, Terrence Kantner, Ravindra Pathak, XiaoBo Sheng, Fabio Simoes, Hiteshri Makwana, Ricardo Resende, Elena de Juan, Alan Jenkins, David Morris, Aurelie Michelet, Frances Jewitt, Felicity Rudge, Nicolas Camper, Anaïs Manin, William McDowell, Martin Pabst, Antony Godwin, Mark Frigerio, Matthew Bird   +22 more
doaj   +1 more source

Exquisite Tumor Targeting by Salmonella A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model. [PDF]

, 2020
Adult pleomorphic rhabdomyosarcoma (RMS) is a rare and malignant mesenchymal tumor. Recently, we developed a patient-derived orthotopic xenograft (PDOX) model of adult pleomorphic RMS.
Dry, Sarah M, Hayashi, Katsuhiro, Higuchi, Takashi, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kimura, Hiroaki, Kiyuna, Tasuku, Li, Yunfeng, Miwa, Shinji, Miyake, Kentaro, Miyake, Masuyo, Nelson, Scott D, Singh, Shree Ram, Tsuchiya, Hiroyuki, Yamamoto, Norio, Zhao, Ming   +16 more
core  

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Case Report: Eyelid reconstruction using intact fish skin xenograft following periorbital necrotizing fasciitis

Frontiers in Ophthalmology
Periorbital necrotizing fasciitis (NF) is a rare, vision-threatening soft tissue infection that requires rapid antimicrobial treatments to minimize devastating soft tissue destruction, and debridement of affected tissue results in extensive defects ...
Molly Shott, Diane Wang, John Nguyen
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection: Marked stimulation of IgM^++bright/IgD^+dull splenic B cells [PDF]

, 1993
Normal Lewis rat serum contains antibodies (IgM > IgG) that bind to hamster leukocytes and endothelial cells. Transplantation of either the heart or liver from hamster rat results in release of hamster hematolymphoid cells from the graft, which lodge in ...
Celli, S, Demetris, AJ, Fung, JJ, Langer, A, Murase, N, Starzl, TE, Valdivia, LA, Woo, J   +7 more
core  

A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. [PDF]

, 2017
In the present study, we evaluated the efficacy of trabectedin (TRAB) and temozolomide (TEM) compared to cisplatinum (CDDP) on a patient-derived orthotopic xenogrraft (PDOX) of a lung-metastasis from an osteosarcoma of a patient who failed CDDP therapy ...
Dry, Sarah M, Eilber, Fritz C, Elliott, Irmina, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Yunfeng, Miyake, Kentaro, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Singh, Arun S, Tsuchiya, Hiroyuki, Yanagawa, Jane, Zhang, Yong   +15 more
core   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

In Vitro and In Vivo Evaluation of Alectinib-Loaded Dendrimer Nanoparticles as a Drug Delivery System for Non-Small Cell Lung Carcinoma

Pharmaceutics
Background/Objectives: Alectinib, a second-generation tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer (NSCLC), exhibits suboptimal oral bioavailability, primarily attributable to its inherently low aqueous solubility ...
Mahmood R. Atta, Israa Al-Ani, Ibrahim Aldeeb, Khaldun M. AlAzzam, Tha’er Ata, Mohammad A. Almullah, Enas Daoud, Feras Al-Hajji   +7 more
doaj   +1 more source